Table 4. The anti-hyperlipidemic action of MGO is associated with camphene.

	Rat Group				Percent change
Plasma lipid	(A)	(B)	(C)	(D)	+Mixture
content (mg/dl)	Placebo	Triton WR-1339	+Mixture A	+Mixture B	A	B
			+Triton WR-1339	+Triton WR-1339
Total cholesterol	65.1±6.9	262.9±32.3	263.4±23.7ns	156.7±12.3***	+1.2	−40.4
LDL-cholesterol	16.4±2.8	47.6±9.1	45.4±10.7ns	18.5±2.7***	−4.7	−61.1
Triglycerides	130.2±22.6	1950.8±191.1	1976±140.7ns	888.7±99.3***	+1.3	−54.4

The placebo group (A) was administered 1 ml carrier alone. The Triton WR-1339 group (B) was administered 1 ml carrier and one h later 1 ml of Triton WR-1339 (200 mg/kg). Animals in (C) and (D) received Mixture A and Mixture B, respectively, in 1 ml carrier and one hour later received Triton WR-1339. Mixture A consisted of α-pinene, β-pinene, myrcene, β-caryophyllene and linalool; and Mixture B consisted of Mixture A+camphene. The constituents in Mixtures A and B were present at concentrations identical to those contained in the 4% MGO dose. The percent change caused by Mixture A and B treatments is expressed relative to measurement in the group of Triton WR-1339-treated rats (B), which was defined as 100%. The values represent mean ± SD of six rats. Significantly different values were obtained in Mixture B-treated rats compared to Triton WR-1339-treated rats with p<0.001 (***) by the Student-Newmann-Keuls test. Values of Mixture A-treated rats vs Triton WR-1339-treated rats were non significant, ns (p>0.05).